Cost projections for implementation of safety interventions to prevent transfusion-transmitted Zika virus infection in the United States

Transfusion

Volumn 57, Issue , 2017, Pages 1625-1633

  Ellingson, Katherine D ^a,b   Sapiano, Mathew R P ^a   Haass, Kathryn A ^a   Savinkina, Alexandra A ^a,c   Baker, Misha L ^a,d   Henry, Richard A ^e   Berger, James J ^e   Kuehnert, Matthew J ^a   Basavaraju, Sridhar V ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^d NORTHROP GRUMMAN CORPORATION   (United States)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APHERESIS; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; ERYTHROCYTE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; SCREENING; TORQUE TENO VIRUS INFECTION; UNITED STATES; VASCULARIZATION; ZIKA FEVER; ZIKA VIRUS; ADVERSE EFFECTS; BLOOD; BLOOD TRANSFUSION; DONOR SELECTION; ECONOMICS; MOLECULAR DIAGNOSIS; PROCEDURES; SUPPLY AND DISTRIBUTION; TORQUE TENO VIRUS 1; ZIKA VIRUS INFECTION;

VIRUS RNA;

BLOOD DONORS; BLOOD TRANSFUSION; DONOR SELECTION; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; RNA, VIRAL; TORQUE TENO VIRUS; UNITED STATES; ZIKA VIRUS INFECTION;

EID: 85020251003     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14164     Document Type: Article

References (36)

1. Kuehnert MJ, Epstein JS. Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefront. Transfusion 2016;56:1669-72.
2. Fauci AS, Morens DM. Zika virus in the Americas--yet another arbovirus threat. N Engl J Med 2016;374:601-4.
3. Rasmussen SA, Jamieson DJ, Honein MA, et al. Zika virus and birth defects--reviewing the evidence for causality. N Engl J Med 2016;374:1981-7.
4. Ventura CV, Maia M, Dias N, et al. Zika: neurological and ocular findings in infant without microcephaly. Lancet 2016;387:2502.
5. Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016;387:1531-9.
6. Dirlikov E, Major CG, Mayshack M, et al. Guillain-Barré syndrome during ongoing Zika virus transmission - Puerto Rico, January 1-July 31, 2016. MMWR Morb Mortal Wkly Rep 2016;65:910-4.
7. Case counts in the US [Internet]. Atlanta: Centers for Disease Control and Prevention; 2017 [cited 2017 Feb 6]. Available from: https://www.cdc.gov/zika/geo/united-states.html.
8. Hayes EB. Zika virus outside Africa. Emerg Infect Dis 2009;15:1347-50.
9. Freour T, Mirallie S, Hubert B, et al. Sexual transmission of Zika virus in an entirely asymptomatic couple returning from a Zika epidemic area, France, April 2016. Euro Surveill 2016;21.
10. Donor screening recommendations to reduce the risk of transmission of Zika virus by human cells, tissues, and cellular and tissue-based products: guidance for industry. Silver Spring (MD): U.S. Food and Drug Administration; 2016.
11. Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components: guidance for industry. Silver Spring (MD): U.S. Food and Drug Administration; 2016.
12. Barjas-Castro ML, Angerami RN, Cunha MS, et al. Probable transfusion-transmitted Zika virus in Brazil. Transfusion 2016;56:1684-8.
13. Motta IJ, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med 2016;375:1101-3.
14. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect 2014;20:O595-6.
15. Gallian P, Cabié A, Richard P, et al. Zika virus in asymptomatic blood donors in Martinique. Blood 2017;129:263-6.
16. Kuehnert MJ, Basavaraju SV, Moseley RR, et al. Screening of blood donations for Zika virus infection - Puerto Rico, April 3-June 11, 2016. MMWR Morb Mortal Wkly Rep 2016;65:627-8.
17. Hennessey M, Fischer M, Staples JE. Zika virus spreads to new areas - region of the Americas, May 2015-January 2016. MMWR Morb Mortal Wkly Rep 2016;65:55-8.
18. Likos A, Griffin I, Bingham AM, et al. Local mosquito-borne transmission of Zika Virus - Miami-Dade and Broward counties, Florida, June-August 2016. MMWR Morb Mortal Wkly Rep 2016;65:1032-8.
19. Guidance for industry: use of nucleic acid tests to reduce the risk of transmission of West Nile virus from donors of whole blood and blood components intended for transfusion. Silver Spring (MD): U.S. Food and Drug Administration; 2009.
20. Guidance for industry: nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV): testing, product disposition, and donor deferral and reentry. Silver Spring (MD): U.S. Food and Drug Administration; 2010.
21. Monaghan AJ, Morin CW, Steinhoff DF, et al. On the seasonal occurrence and abundance of the Zika virus vector mosquito Aedes aegypti in the contiguous United States. PLoS Curr 2016;8.
22. USGS and CDC disease maps [Internet]. Reston (VA): U.S. Department of the Interior, U.S. Geological Survey; 2016 [cited yyyy mmm dd]. Available from: https://diseasemaps.usgs.gov/index.html.
23. Ellingson K, Sapiano M, Haass K, Savinkina A, Baker M, Chang K, Henry R, Berger J, Kuehnert M, Basavaraju S. Continued Decline in Blood Collection and Transfusion in the United States – 2015. Transfusion 2017 (In Press).
24. Code of Federal Regulations, Charging for investigational new drugs under an IND, title 21, sec. 312.8.
25. Jackson BR, Busch MP, Stramer SL, et al. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003;43:721-9.
26. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004;86:28-40.
27. Shehata N, Kohli M, Detsky A. The cost-effectiveness of screening blood donors for malaria by PCR. Transfusion 2004;44:217-28.
28. Custer B, Busch MP, Marfin AA, et al. The cost-effectiveness of screening the U.S. blood supply for West Nile virus. Ann Intern Med 2005;143:486-92.
29. Population estimates by state and age. Washington (DC): U.S. Census Bureau; 2015.
30. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003;25:2464-86.
31. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010;50:2461-73.
32. Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, et al. Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 2014;54:158-68.
33. 114th meeting of the Blood Products Advisory Committee. Silver Spring (MD): Food and Drug Administration, Center for Biologics Evaluation and Research; 2016.
34. Thomas DL, Sharp TM, Torres J, et al. Local transmission of Zika Virus--Puerto Rico, November 23, 2015-January 28, 2016. MMWR Morb Mortal Wkly Rep 2016;65:154-8.
35. Jacobs MR, Lazarus HM, Maitta RW. The safety of the blood supply--time to raise the bar. N Engl J Med 2015;373:882.
36. Cerus announces agreement with BARDA for potential funding of up to approximately $180 million to advance its INTERCEPT red blood cell program [press release]. Concord (CA): Cerus Corp.; 2016.